These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
905 related articles for article (PubMed ID: 29506471)
1. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471 [TBL] [Abstract][Full Text] [Related]
2. Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations. Choi MC; Heo JH; Jang JH; Jung SG; Park H; Joo WD; Lee C; Lee JH; Lee JM; Hwang YY; Kim SJ Int J Gynecol Cancer; 2015 Oct; 25(8):1386-91. PubMed ID: 26402875 [TBL] [Abstract][Full Text] [Related]
3. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
4. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700 [TBL] [Abstract][Full Text] [Related]
5. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687 [TBL] [Abstract][Full Text] [Related]
6. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different? Reitsma W; de Bock GH; Oosterwijk JC; ten Hoor KA; Hollema H; Mourits MJ Int J Gynecol Cancer; 2012 May; 22(4):579-85. PubMed ID: 22274543 [TBL] [Abstract][Full Text] [Related]
8. Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications. Casey MJ; Bewtra C; Lynch HT; Snyder CL; Stacey M Int J Gynecol Cancer; 2015 May; 25(4):650-6. PubMed ID: 25756400 [TBL] [Abstract][Full Text] [Related]
9. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854 [TBL] [Abstract][Full Text] [Related]
10. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802 [TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974 [TBL] [Abstract][Full Text] [Related]
13. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer]. Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312 [No Abstract] [Full Text] [Related]
14. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer. Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643 [TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study. Kitson SJ; Bafligil C; Ryan NAJ; Lalloo F; Woodward ER; Clayton RD; Edmondson RJ; Bolton J; Crosbie EJ; Evans DG Eur J Cancer; 2020 Sep; 136():169-175. PubMed ID: 32698099 [TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744 [TBL] [Abstract][Full Text] [Related]
17. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds. Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920 [TBL] [Abstract][Full Text] [Related]
18. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Bruchim I; Amichay K; Kidron D; Attias Z; Biron-Shental T; Drucker L; Friedman E; Werner H; Fishman A Int J Gynecol Cancer; 2010 Oct; 20(7):1148-53. PubMed ID: 21206239 [TBL] [Abstract][Full Text] [Related]
19. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing. Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862 [TBL] [Abstract][Full Text] [Related]
20. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]